The purpose of this study is to evaluate Efficacy and Safety of oral intake of Naftopidil 75mg once daily for the improving clearance of ureteral or renal stones.
Prospective, Single-center, Double blind, Randomized controlled trial Treatment \- Oral Naftopidil 75 mg once daily are given to the patients who are scheduled for shockwave lithotripsy (ESWL) because of ureteral or renal stones. Follow up Assessments including X-ray(KUB), visual analogue pain scale, are done 2, 4, and 6 weeks after the ESWL.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
130
Samsung Medical Center
Seoul, South Korea
Difference of the treatment success rate in two weeks after ESWL between treatment group and placebo group
Treatment success is defined as no or less than 3 mm size remnant stone
Time frame: 2 weeks after ESWL
Difference of the treatment success rate after ESWL between treatment group and placebo group
Treatment success is defined as no or less than 3 mm size remnant stone
Time frame: 4, 6 weeks after ESWL
Adverse Event
Rate of total Adverse Events and Adverse Events relevant to Investigational drug
Time frame: 2,4,6weeks
pain scale
visual analogue pain scale due to urinary stone
Time frame: baseline, 2, 4, 6 weeks
rate of additional intervention
incidence of additional intervention for the urinary stone ex\> ureteral stent insertion, percutaneous nephrostomy, ureteroscopic ureterolithotomy, percutaneous nephrolithotomy, laparoscopic stone removal and so on
Time frame: 6 week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.